Methods for the treatment of neurodegeneration

Patent metadata

Field	Value
Publication number	US-10464996-B2
Application number	US-201414890865-A
Country	US
Kind code	B2
Filing date	May 13, 2014
Priority date	May 13, 2013
Publication date	Nov 5, 2019
Grant date	Nov 5, 2019

Abstract

The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an α 1,3 and/or α 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuAc-α 2,6-Gal or NeuAc-α 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in part, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.

First claim

What is claimed is:

1. A method for the treatment of neurodegeneration associated with Alzheimer's disease or a multifocal motor neuropathy, the method comprising administering to a subject in need thereof a preparation comprising enzymatically sialylated IVIG, wherein at least 70% of branched glycans on the Fc region of the enzymatically sialylated IVIG in the preparation have at least one galactose connected to a respective terminal sialic acid on both the α 1,3 arm and the α 1,6 arm of the branched glycan, linked to the galactose via a NeuAc-α 2,6-Gal terminal linkage.

2. The method of claim 1 , wherein the preparation is administered in a pharmaceutical formulation comprising the enzymatically sialylated IVIG and a pharmaceutically acceptable carrier or diluent.

3. The method of claim 1 , wherein the neurodegeneration is associated with multifocal motor neuropathy.

4. The method of claim 1 , wherein the neurodegeneration is associated with Alzheimer's disease.

5. The method of claim 2 , wherein the neurodegeneration is associated with multifocal motor neuropathy.

6. The method of claim 2 , wherein the neurodegeneration is associated with Alzheimer's disease.

Assignees

• Momenta Pharmaceuticals Inc

Inventors

• Prod'Homme Thomas E
• Ling Leona E
• Bosques Carlos J
• Manning Anthony
• Kaundinya Ganesh

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C07K16/06 Primary

  from serum · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• A61K2039/54

  characterised by the route of administration · CPC title

• A61K2039/505

  comprising antibodies · CPC title